Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care
CompletedOBSERVATIONAL
Enrollment
480
Participants
Timeline
Start Date
January 31, 2005
Conditions
Escherichia Coli InfectionsKlebsiella Infections
Interventions
DRUG
vancomycin-resistant enterococci and ESBL
Trial Locations (1)
431-070
Gyunggi-do
All Listed Sponsors
lead
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
NCT00167986 - Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care | Biotech Hunter | Biotech Hunter